MedTrace Logo

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

NCT01323751 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-04-06

No results posted yet for this study

Summary

Phase 1(a \& b): To evaluate the side effects and determine the best dose of oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

Phase 2a: To determine the objective response rate of oral ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

Conditions

Interventions

DRUG

ACY-1215

Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Sagar Lonial, MD · Winship Cancer Institute, Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2016-12-31
Completion
2016-12-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01323751 on ClinicalTrials.gov